<DOC>
	<DOCNO>NCT00000944</DOCNO>
	<brief_summary>The purpose study determine combination anti-HIV drug treatment regimen indinavir plus lamivudine ( 3TC ) plus zidovudine ( ZDV ) effective treat HIV reduce chance pass HIV mother child . This study also examine combination well tolerate HIV-positive pregnant woman combination 3TC plus ZDV safe newborn . Previous study adult child show indinavir plus 3TC plus ZDV reduce amount HIV blood . Most HIV-positive pregnant woman usually take ZDV treat HIV reduce chance give HIV baby . The combination drug study may effective ZDV alone .</brief_summary>
	<brief_title>A Study Evaluate Safety Tolerance Combination Anti-HIV Drug Therapy ( Indinavir , Lamivudine , Zidovudine ) HIV-Positive Pregnant Women Their Infants</brief_title>
	<detailed_description>Despite dramatic reduction perinatal HIV transmission follow administration ZDV mother infant , new , effective strategy need . An increase number woman may require combination antiretroviral therapy disease may resistant ZDV , may high viral load , may previously transmit HIV infant ZDV monotherapy . The initiation triple combination therapy , include protease inhibitor indinavir , gestation may effective reduce maternal virus load prior delivery , thereby potentially benefit mother child . Women : Antepartum ( active labor ) : Indinavir plus 3TC plus ZDV . Intrapartum ( active labor cord clamp ) : 3TC plus ZDV . Postpartum ( cord clamp 12 week ) : Indinavir plus 3TC plus ZDV . Infants : 3TC plus ZDV soon oral intake tolerate ( preferably within 12 hour birth ) continue 6 week . [ AS PER AMENDMENT 1/27/99 : For maternal dosing , one Combivir tablet bid substitute individual formulation 3TC ZDV . For mother receive Combivir antepartum period , Combivir hold labor delivery , separate formulation ZDV 3TC use . Patients prematurely discontinue study treatment continue follow study duration study . ]</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<mesh_term>Indinavir</mesh_term>
	<criteria>Inclusion Criteria Women may eligible study : Are HIVpositive . Have pregnant 1428 week ( 1st 2nd trimester ) . Have normal ultrasound exam screen study . Are able drink 6 glass water day throughout study . Are least 13 year old ( need consent parent guardian 18 ) . Exclusion Criteria Women eligible study : Can take 3TC ZDV . Have active opportunistic ( HIVassociated ) bacterial infection study entry . Have chronic diarrhea . Have epilepsy cancer . Are pregnant 2 child ( triplet , etc . ) Have risk factor premature birth , problem pregnancy . Have immediate lifethreatening illness . Have severe anemia illness require blood product . Have history chronic liver kidney disease . Plan breastfeed .</criteria>
	<gender>Female</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Pregnancy</keyword>
	<keyword>Pregnancy Complications , Infectious</keyword>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>Zidovudine</keyword>
	<keyword>HIV Protease Inhibitors</keyword>
	<keyword>Lamivudine</keyword>
	<keyword>Indinavir</keyword>
	<keyword>Disease Transmission , Vertical</keyword>
	<keyword>Anti-HIV Agents</keyword>
</DOC>